Compare Citius Pharmaceuticals Inc (CTXR) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Direxion Daily S&P 500 Bull 3X Shares trades at $297.97 (market cap $7.36B). The key difference: Direxion Daily S&P 500 Bull 3X Shares is far larger — about 540.4× Citius Pharmaceuticals Inc's market cap, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| CTXR | SPXL | |
|---|---|---|
Market Cap | $13.62M | $7.36B |
Volume | 132,438 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $301.38 |
52-Week Low | $0.48 | $170.20 |
Typical Hold Time | 17 Days | 32 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
SPXL trades at $297.97, up 0.38% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 66.91 suggesting mild overbought conditions. Support levels begin at $289 with resistance at $297. Recent news highlights S&P 500 valuation debates and profit growth expectations shifting from 35% in 2026 to 15% in 2027.
Outlook remains cautiously optimistic given the ETF's leveraged exposure to S&P 500 momentum. Key risks include market concentration in top holdings and potential profit growth deceleration. The technical setup favors continued upside if $297 resistance breaks, while failure to hold $289 support could signal near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
